Zymeworks (ZYME) Long-Term Deferred Tax (2021 - 2026)
Zymeworks recorded quarterly Long-Term Deferred Tax of $4.7 million in Q1 2026, little changed quarter-over-quarter from $4.7 million in Q4 2025, and down 2.93% year-over-year from $4.8 million in Q1 2025.
Zymeworks' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax fell 2.93% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (down 2.93% YoY), while the FY2025 annual figure was $4.7 million, up 7.34% from the prior year.
- Long-Term Deferred Tax came in at $4.7 million for Q1 2026 at Zymeworks, roughly flat from $4.7 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $4.9 million in Q3 2025 to a low of $1.3 million in Q3 2023.
- A 5-year average of $3.5 million and a median of $3.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
- Across the five-year window, Long-Term Deferred Tax plunged 56.57% in 2023 and soared 219.85% in 2024, its largest moves.
- Zymeworks' Long-Term Deferred Tax stood at $1.3 million in 2022, then soared by 168.77% to $3.6 million in 2023, then advanced by 21.3% to $4.4 million in 2024, then grew by 7.34% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $4.7 million, $4.7 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 4.71 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.77 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | 3.95 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 3.03 Mn |
| Dec 31, 2021 | 3.07 Mn |